S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
S&P 500   4,288.99 (-1.12%)
DOW   33,713.03 (-0.86%)
QQQ   355.48 (-1.15%)
AAPL   172.79 (-1.87%)
MSFT   312.82 (-1.49%)
META   299.70 (-0.38%)
GOOGL   127.72 (-2.59%)
AMZN   126.93 (-3.31%)
TSLA   247.38 (+0.16%)
NVDA   425.68 (+0.82%)
NIO   8.52 (+2.04%)
BABA   86.47 (-0.86%)
AMD   96.78 (-0.62%)
T   14.96 (-0.66%)
F   12.53 (-0.40%)
MU   68.20 (-0.55%)
CGC   1.02 (+8.19%)
GE   110.79 (-0.83%)
DIS   80.59 (-0.52%)
AMC   8.29 (+1.84%)
PFE   32.79 (-0.58%)
PYPL   58.73 (-0.22%)
NFLX   384.04 (-0.20%)
LON:INS

Instem (INS) Share Forecast, Price & News

GBX 825.10
+0.10 (+0.01%)
(As of 04:00 PM ET)
Compare
Today's Range
825
▼
825.10
50-Day Range
588
▼
830
52-Week Range
550
▼
830
Volume
231,451 shs
Average Volume
72,442 shs
Market Capitalization
£188.95 million
P/E Ratio
5,893.57
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlines

INS stock logo

About Instem (LON:INS) Stock

Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

INS Price History

INS Stock News Headlines

September 15, 2023 | marketwatch.com
Instem Swung to 1H Pretax Loss Amid Higher Costs
September 1, 2023 | thetimes.co.uk
Instem board ‘absurd’ to back £203m bid
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 1, 2023 | msn.com
ALEX BRUMMER: Investors who shunned UK
August 31, 2023 | finanznachrichten.de
Samson Rock Capital LLP - Re-issue: Form 8.3 - Instem Plc
August 31, 2023 | finance.yahoo.com
Form 8.3 - INS LN
August 31, 2023 | uk.finance.yahoo.com
Samson Rock Capital LLP - Form 8.3 - Instem Plc
August 30, 2023 | msn.com
Instem bought by French private equity firm Archimed SAS in £200m deal
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
August 30, 2023 | usnews.com
UK's Instem Soars on $257 Million Take-Private Offer From French PE Firm
August 30, 2023 | theguardian.com
Staffordshire-based Instem bought by private equity group Archimed for £203m
August 30, 2023 | lse.co.uk
AIM WINNERS & LOSERS: Instem soars on GBP200 million takeover
August 30, 2023 | lse.co.uk
TOP NEWS: Instem accepts GBP200 million takeover offer from Archimed
August 30, 2023 | reuters.com
UK's Instem soars on $257 mln take-private offer from French PE firm
August 30, 2023 | finance.yahoo.com
UK's Instem shares pop on $257 million take-private deal from French firm
August 30, 2023 | finance.yahoo.com
Form 8.3 - INSTEM PLC
August 30, 2023 | markets.businessinsider.com
Instem Agrees To Be Acquired By ARCHIMED In GBP 203 Mln Deal
August 30, 2023 | marketwatch.com
Instem Agrees to GBP203 Mln Takeover by Ichor Management
August 15, 2023 | marketwatch.com
Instem Sees 2023 Performance In Line With Its Views After 1H Revenue Growth
July 4, 2023 | msn.com
Bengaluru: NCBS launches Rohini Nilekani Centre for Brain and Mind for research on severe mental illnesses
June 28, 2023 | marketwatch.com
Instem's Executive Pay, Auditor Reappointment Get Low Shareholder Support at AGM
June 2, 2023 | finance.yahoo.com
Instem plc (LON:INS) Shares Could Be 32% Below Their Intrinsic Value Estimate
May 17, 2023 | finance.yahoo.com
We Ran A Stock Scan For Earnings Growth And Instem (LON:INS) Passed With Ease
May 15, 2023 | lse.co.uk
Instem acquires new platform following annual profit growth
May 15, 2023 | marketwatch.com
Instem 2022 Pretax Rose; Gets ToxHub Rights
May 13, 2023 | marketwatch.com
Computational Toxicology Software Market Likely to Enjoy Remarkable Growth with Instem (Leadscope Inc), Lhasa Limited, MultiCASE, Inotiv
May 12, 2023 | lse.co.uk
Instem renews long-term contract with US National Toxicology Program
See More Headlines
Receive INS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:INS
CUSIP
N/A
CIK
N/A
Web
www.instem.com
Phone
+44-1785-825600
Fax
N/A
Employees
500
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX 0.14
Trailing P/E Ratio
5,893.57
Forward P/E Ratio
17.83
P/E Growth
1.89
Net Income
£3.34 million
Net Margins
5.50%
Pretax Margin
N/A
Return on Equity
6.35%
Return on Assets
4.62%

Debt

Debt-to-Equity Ratio
3.47
Current Ratio
0.95
Quick Ratio
0.84

Sales & Book Value

Annual Sales
£61.63 million
Price / Sales
3.07
Cash Flow
GBX 54.09 per share
Price / Cash Flow
15.25
Book Value
GBX 239 per share
Price / Book
3.45

Miscellaneous

Outstanding Shares
22,900,000
Free Float
N/A
Market Cap
£188.95 million
Optionable
Not Optionable
Beta
0.40
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Phil J. Reason (Age 61)
    CEO & Exec. Director
    Comp: $300k
  • Mr. Nigel John Goldsmith (Age 61)
    CFO, Sec. & Exec. Director
    Comp: $166k
  • Ms. Marybeth Thompson
    Chief Operating Officer
  • Dr. Gordon Smith Baxter
    Chief Scientific Officer
  • Mr. Mark Poggi M.B.A.
    Ph.D., Exec. VP of Global Sales
  • Ms. Eve Leconte
    Chief People & Culture Officer
  • Mr. Mike Harwood
    Chief Product Officer
  • Mr. Gregor Grant
    Exec. VP of Preclinical Solutions
  • Mr. John Leveille
    Exec. VP of Clinical Trial Acceleration

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













INS Stock - Frequently Asked Questions

How have INS shares performed in 2023?

Instem's stock was trading at GBX 710 at the beginning of the year. Since then, INS stock has increased by 16.2% and is now trading at GBX 825.10.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Instem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Instem investors own include Abeona Therapeutics (ABEO), ARCA biopharma (ABIO), Apollo Investment (AINV), Alico (ALCO), Corindus Vascular Robotics (CVRS), DSS (DSS), Evans Bancorp (EVBN), The LGL Group (LGL) and UQM Technologies (UQM).

What is Instem's stock symbol?

Instem trades on the London Stock Exchange (LON) under the ticker symbol "INS."

How do I buy shares of Instem?

Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Instem's stock price today?

One share of INS stock can currently be purchased for approximately GBX 825.10.

How much money does Instem make?

Instem (LON:INS) has a market capitalization of £188.95 million and generates £61.63 million in revenue each year. The company earns £3.34 million in net income (profit) each year or GBX 0.14 on an earnings per share basis.

How many employees does Instem have?

The company employs 500 workers across the globe.

How can I contact Instem?

Instem's mailing address is Diamond Way, Stone Business Park, STONE, ST15 0SD, United Kingdom. The official website for the company is www.instem.com. The company can be reached via phone at +44-1785-825600.

This page (LON:INS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -